Socinski, M. A., & Steins, M. (2016). NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC. Annals of oncology, 27, . https://doi.org/10.1093/annonc/mdw435.39
Chicago-Zitierstil (17. Ausg.)Socinski, Mark A., und Martin Steins. "NSCLC, MetastaticCheckMate 026: A Phase 3 Trial of Nivolumab Vs Investigator's Choice (IC) of Platinum-based Doublet Chemotherapy (PT-DC) as First-line Therapy for Stage Iv/recurrent Programmed Death Ligand 1 (PD-L1)−positive NSCLC." Annals of Oncology 27 (2016). https://doi.org/10.1093/annonc/mdw435.39.
MLA-Zitierstil (9. Ausg.)Socinski, Mark A., und Martin Steins. "NSCLC, MetastaticCheckMate 026: A Phase 3 Trial of Nivolumab Vs Investigator's Choice (IC) of Platinum-based Doublet Chemotherapy (PT-DC) as First-line Therapy for Stage Iv/recurrent Programmed Death Ligand 1 (PD-L1)−positive NSCLC." Annals of Oncology, vol. 27, 2016, https://doi.org/10.1093/annonc/mdw435.39.